<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04940364</url>
  </required_header>
  <id_info>
    <org_study_id>R3918-HV-20117</org_study_id>
    <secondary_id>2021-001794-23</secondary_id>
    <nct_id>NCT04940364</nct_id>
  </id_info>
  <brief_title>A Study to Examine the Safety, Tolerability and Biological Effects of Single Doses of Subcutaneously and Intravenously Administered Pozelimab as Monotherapy and in Combination With Single Doses of Subcutaneously Administered Cemdisiran in Adult Japanese Healthy Volunteers</brief_title>
  <official_title>An Open-Label Parallel-Dose Study of the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Single Doses of Subcutaneously and Intravenously Administered Pozelimab as Monotherapy and in Combination With Single Doses of Subcutaneously Administered Cemdisiran in Japanese Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Regeneron Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Regeneron Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of the study is to assess the concentration-time profiles of total&#xD;
      pozelimab, total C5, cemdisiran, and cemdisiran metabolite(s) in Japanese adult participants&#xD;
      following single doses of intravenous (IV) and subcutaneous (SC) pozelimab and SC cemdisiran&#xD;
      when administered on the same day or sequentially 28 days apart.&#xD;
&#xD;
      The secondary objectives of the study are:&#xD;
&#xD;
        -  To evaluate the safety and tolerability of pozelimab alone and in combination with&#xD;
           cemdisiran in healthy Japanese adult participants&#xD;
&#xD;
        -  To assess the pharmacodynamic (PD) profile of pozelimab alone and in combination with&#xD;
           cemdisiran in healthy Japanese adult participants&#xD;
&#xD;
        -  To assess the immunogenicity of pozelimab and cemdisiran in healthy Japanese adult&#xD;
           participants&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 4, 2021</start_date>
  <completion_date type="Anticipated">February 8, 2022</completion_date>
  <primary_completion_date type="Anticipated">February 8, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Concentrations of pozelimab in serum over time</measure>
    <time_frame>Up to 20 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Concentrations of cemdisiran in plasma over time.</measure>
    <time_frame>Up to 20 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The incidence and severity of treatment-emergent adverse events (TEAE) in subjects administered pozelimab with/without cemdisiran</measure>
    <time_frame>Up to 20 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentrations of total C5 in plasma over time</measure>
    <time_frame>Up to 20 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in CH50 over time</measure>
    <time_frame>Up to 20 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of treatment-emergent anti-drug antibodies (ADA) to pozelimab</measure>
    <time_frame>Up to 20 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of treatment-emergent ADA to cemdisiran</measure>
    <time_frame>Up to 20 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pozelimab: Single-dose SC on day 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pozelimab: Single-dose IV on day 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pozelimab: Single-dose SC on day 29 Cemdisiran: Single-dose SC on day 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pozelimab: Single-dose SC on day 1 Cemdisiran: Single-dose SC on day 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Optional Pozelimab: Single-dose SC on day 1 or day 29 Cemdisiran: Single-dose SC on day 1</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pozelimab</intervention_name>
    <description>Administered intravenous (IV) or subcutaneous (SC) per protocol</description>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_label>Cohort 4</arm_group_label>
    <arm_group_label>Cohort 5</arm_group_label>
    <other_name>REGN3918</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cemdisiran</intervention_name>
    <description>Administered SC per protocol</description>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_label>Cohort 4</arm_group_label>
    <arm_group_label>Cohort 5</arm_group_label>
    <other_name>ALN-CC5</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          1. Japanese participant must be:&#xD;
&#xD;
               1. Be Japanese, born in Japan, and have both biologic parents and 4 biologic&#xD;
                  grandparents who are ethnically Japanese and born in Japan&#xD;
&#xD;
               2. Have maintained a Japanese lifestyle, with no significant change since leaving&#xD;
                  Japan, including having access to Japanese food and adhering to a Japanese diet&#xD;
&#xD;
               3. Living &lt; 10 years outside of Japan&#xD;
&#xD;
          2. Has a Body Mass Index (BMI) between 18 and 30 kg/m2 (inclusive) at screening visit&#xD;
&#xD;
          3. Is judged by the investigator to be in good health based on medical history, physical&#xD;
             examination, vital sign measurements, and ECGs performed at screening and/or prior to&#xD;
             administration of initial dose of study drug&#xD;
&#xD;
          4. Is in good health based on laboratory safety testing obtained at the screening visit&#xD;
             Note: Participant with suspected or confirmed Gilbert's disease can be enrolled in the&#xD;
             study&#xD;
&#xD;
          5. Willing to undergo vaccination against N. meningitidis unless participant has&#xD;
             documentation of completed series of vaccinations within the past 2 years of the&#xD;
             screening visit&#xD;
&#xD;
          6. Must have two consecutive negative COVID-19 tests at least 48 hours apart and within 7&#xD;
             days prior to study drug administration Note: The test may be the point of care&#xD;
             quantitative reverse transcriptase polymerase chain reaction (RT-qPCR) test or&#xD;
             approved COVID-19 antigen test at the discretion of the investigator.&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          1. History of clinically significant cardiovascular, respiratory, hepatic, renal,&#xD;
             gastrointestinal, endocrine, hematological, psychiatric or neurological disease, as&#xD;
             assessed by the investigator as defined in the protocol&#xD;
&#xD;
          2. Presents any concern to the study investigator that might confound the results of the&#xD;
             study or poses an additional risk to the participant by their participation in the&#xD;
             study&#xD;
&#xD;
          3. Hospitalization (&gt;24 hour) for any reason within 30 days of the screening visit&#xD;
&#xD;
          4. Has a confirmed positive drug test result at the screening visit and/or prior to&#xD;
             enrollment; or a history of alcohol and/or drug abuse within a year prior to the&#xD;
             screening visit&#xD;
&#xD;
          5. Is positive for human immunodeficiency virus (HIV), hepatitis B surface antigen&#xD;
             (HBsAg), or hepatitis B core antibody (HBcAb) at the screening visit&#xD;
&#xD;
          6. Is positive for hepatitis C antibody and positive for qualitative (i.e., detected)&#xD;
             hepatitis C virus (HCV) RNA test at the screening visit&#xD;
&#xD;
          7. Within the previous 2 months of the screening visit has a history of bacterial,&#xD;
             protozoal, viral or parasite infection (including COVID-19) and/or persistent chronic&#xD;
             or active recurring infection which require treatment with antibiotics, antivirals, or&#xD;
             antifungals&#xD;
&#xD;
          8. Known or suspected COVID-19 disease at screening and/or prior to 1st dose&#xD;
             administration&#xD;
&#xD;
        NOTE: Other protocol-defined Inclusion and Exclusion criteria apply&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trial Management</last_name>
    <role>Study Director</role>
    <affiliation>Regeneron Pharmaceuticals</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Clinical Trials Administrator</last_name>
    <phone>844-734-6643</phone>
    <email>clinicaltrials@regeneron.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Regeneron Research Site</name>
      <address>
        <city>London</city>
        <zip>SE1 1YR</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>June 17, 2021</study_first_submitted>
  <study_first_submitted_qc>June 17, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 25, 2021</study_first_posted>
  <last_update_submitted>August 5, 2021</last_update_submitted>
  <last_update_submitted_qc>August 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>All Individual Patient Data (IPD) that underlie publicly available results will be considered for sharing</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_info_type>Analytic Code</ipd_info_type>
    <ipd_time_frame>When Regeneron has received marketing authorization from major health authorities (e.g., FDA, European Medicines Agency (EMA), Pharmaceuticals and Medical Devices Agency (PMDA), etc.) for the product and indication, has made the study results publicly available (e.g., scientific publication, scientific conference, clinical trial registry), has the legal authority to share the data, and has ensured the ability to protect participant privacy.</ipd_time_frame>
    <ipd_access_criteria>Qualified researchers can submit a proposal for access to individual patient or aggregate level data from a Regeneron-sponsored clinical trial through Vivli. Regeneron's Independent Research Request Evaluation Criteria can be found at: https://www.regeneron.com/sites/default/files/Regeneron-External-Data-Sharing-Policy-and-Independent-Research-Request-Evaluation-Criteria.pdf</ipd_access_criteria>
    <ipd_url>https://vivli.org/</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

